Live Earnings Conference Call: Supernus Pharmaceuticals will host a live Q1 2025 earnings call on May 6, 2025 at 4:30PM ET. Follow this link to get details and listen to Supernus Pharmaceuticals' Q1 2025 earnings call when it goes live. Get details. Supernus Pharmaceuticals (SUPN) News Today $32.39 -0.45 (-1.37%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$33.49 +1.10 (+3.40%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Supernus Pharmaceuticals Earnings: What To Look For From SUPNMay 5 at 1:19 PM | msn.comAristotle Capital Boston LLC Sells 118,358 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Aristotle Capital Boston LLC lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,075,868 shares of the specialty pharmaceuticMay 5 at 7:01 AM | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Raised by PDT Partners LLCPDT Partners LLC grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 48.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,008 shares of the specialty phMay 2, 2025 | marketbeat.comHsbc Holdings PLC Sells 22,334 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Hsbc Holdings PLC reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 228,030 shares of the specialty pharmaceutical company's stockMay 1, 2025 | marketbeat.comSA analyst downgrades: TSLA, TXN, ORLY, SUPN, KDPApril 30, 2025 | msn.comSupernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade)April 30, 2025 | seekingalpha.comCanada Pension Plan Investment Board Lowers Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Canada Pension Plan Investment Board reduced its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 95.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,700 shares of the specialty pharmaceutical compaApril 29, 2025 | marketbeat.comBarclays PLC Buys 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Barclays PLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 122,849 shares of the specialty pharmaceutical company's stock after acquiring an additApril 29, 2025 | marketbeat.comWells Fargo & Company MN Boosts Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wells Fargo & Company MN boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 63,237 shares of the specialty pharmaceutical companyApril 28, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company's stock, valuedApril 26, 2025 | marketbeat.comSupernus Pharmaceuticals (SUPN) Receives a Buy from TD CowenApril 24, 2025 | markets.businessinsider.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Here's What HappenedSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Here's WhyApril 24, 2025 | marketbeat.comEversept Partners LP Purchases Shares of 105,581 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Eversept Partners LP purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,581 shares of thApril 24, 2025 | marketbeat.comSupernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference ...April 23, 2025 | gurufocus.comSupernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025April 23, 2025 | globenewswire.comEpoch Investment Partners Inc. Increases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Epoch Investment Partners Inc. lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 59.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 85,691 shares of the specialty pharmaceutical compApril 23, 2025 | marketbeat.comAlpha DNA Investment Management LLC Buys Shares of 12,218 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Alpha DNA Investment Management LLC purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,218 shares of the specialty pharmaceutApril 21, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company's stock after acquiring an additional 22,0April 21, 2025 | marketbeat.comFederated Hermes Inc. Has $58,000 Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Federated Hermes Inc. reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 96.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,606 shares of the specialty pharmaceuticalApril 21, 2025 | marketbeat.comSterling Capital Management LLC Has $527,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Sterling Capital Management LLC lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8,619.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,562 shares of the specialty pharmaceutical companApril 20, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Lessened by Russell Investments Group Ltd.Russell Investments Group Ltd. lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,395 shares of the specialty pharmaceuticaApril 19, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by StockNews.comStockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday.April 19, 2025 | marketbeat.comIs Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?April 17, 2025 | insidermonkey.comJPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)JPMorgan Chase & Co. boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 17.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 297,810 shares of the specialty pharmaceuApril 16, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,510,568 shares of theApril 15, 2025 | marketbeat.comRenaissance Technologies LLC Reduces Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Renaissance Technologies LLC trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,598,722 shares oApril 12, 2025 | marketbeat.comNorges Bank Makes New Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Norges Bank acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 125,551 shares of the specialty pharmaceuticalApril 12, 2025 | marketbeat.comQ4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals StocksApril 10, 2025 | msn.comCapula Management Ltd Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Capula Management Ltd bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,574 shares of the specialty pharmaceutApril 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 24th. The tradApril 10, 2025 | marketbeat.comTrexquant Investment LP Sells 20,677 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Trexquant Investment LP reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 21.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,275 shares of the specialty pharmaceutical company'sApril 9, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Arrowstreet Capital Limited Partnership grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 79.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 174,916 shares of the specialty pharmaceutical company's stock after acqApril 9, 2025 | marketbeat.comVanguard Group Inc. Has $222.41 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,150,759 shaApril 7, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Schroder Investment Management GroupSchroder Investment Management Group decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 42.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,657 shApril 5, 2025 | marketbeat.comPrudential Financial Inc. Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Prudential Financial Inc. raised its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,733 shares of the specialty pharmApril 5, 2025 | marketbeat.comSupernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?April 5, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) Raised to "Strong-Buy" at StockNews.comStockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday.April 3, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 34,343 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Pictet Asset Management Holding SA lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 526,252 shares of the specialty pharmApril 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Short Interest Down 17.0% in MarchSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 5,030,000 shares, a decrease of 17.0% from the February 28th total of 6,060,000 shares. Based on an average daily trading volume, of 555,900 shares, the short-interest ratio is currently 9.0 days. Approximately 10.0% of the company's shares are short sold.April 2, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Axiom Investors LLC DEAxiom Investors LLC DE lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 38.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,896 shares of the specialty pharmaceutical company'sApril 2, 2025 | marketbeat.comSei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Sei Investments Co. lowered its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 296,915 shares of the specialty pharmaceutical company's stockMarch 31, 2025 | marketbeat.com41,700 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 41,700 shares of the specialty pharmaceutical compaMarch 30, 2025 | marketbeat.comLoomis Sayles & Co. L P Has $53.05 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Loomis Sayles & Co. L P lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,467,027 shares of the specialMarch 29, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)American Century Companies Inc. increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,140,705 shares of the specialty pharmaceutiMarch 29, 2025 | marketbeat.comUnpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals StocksMarch 27, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) Lowered to "Buy" Rating by StockNews.comStockNews.com cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.March 25, 2025 | marketbeat.com11,282 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Proficio Capital Partners LLCProficio Capital Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,282 shares of the specialtyMarch 25, 2025 | marketbeat.comRaymond James Financial Inc. Takes $6.85 Million Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 189,364 shares of the specialty pharmaceutical company's sMarch 24, 2025 | marketbeat.comFox Run Management L.L.C. Makes New $1.30 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Fox Run Management L.L.C. bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 35,900 shares of the specialty pharmaceutical company's stock, valued at apprMarch 23, 2025 | marketbeat.com12,938 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Purchased by Royce & Associates LPRoyce & Associates LP purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,938 shares of the specialty pharmaceutical company's stock, valuedMarch 23, 2025 | marketbeat.com Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Media Mentions By Week SUPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼0.760.72▲Average Medical News Sentiment SUPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼65▲SUPN Articles Average Week Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JAZZ News PRGO News PCRX News OMER News NKTR News ASMB News CPIX News LLY News JNJ News ABBV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SUPN Stock Free SUPN Stock Alerts